DSGN DESIGN THERAPEUTICS INC

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

CARLSBAD, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2025 RBC Capital Markets Healthcare Conference on Tuesday, May 20, 2025, at 8:00 a.m. ET in New York.

A live webcast of the fireside chat will be available and in the investors section of the company’s website at . The webcast will be archived for at least 30 days following the presentation.

About Design Therapeutics

Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in myotonic dystrophy type-1 and Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.

Contact:

Renee Leck

THRUST Strategic Communications



EN
13/05/2025

Underlying

DSGNDESIGN THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DESIGN THERAPEUTICS INC

 PRESS RELEASE
Free
DSGN DESIGN THERAPEU...

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthc...

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference CARLSBAD, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2025 RBC Capital Markets Healthcare Conference on Tuesday, May 20, 2025, at 8:00 a.m. ET in New York. A live webcast of the fireside chat will be available and in the investors section of the company’s website at . The webcast will ...

15h / 41m 1 EN
 PRESS RELEASE
Free
DSGN DESIGN THERAPEU...

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs ...

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program Well-Capitalized with Cash and Securities of $229.7 Million to Fund Operations Through up to Four Potential Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developi...

May 7, 2025 1 EN
 PRESS RELEASE
Free
DSGN DESIGN THERAPEU...

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Suppor...

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025 CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced favorable data from a Phase 1 single- and multiple-ascending dose (SAD/MAD) trial of DT-168 in healthy volunteers, which ...

May 1, 2025 1 EN
 PRESS RELEASE
Free
DSGN DESIGN THERAPEU...

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corn...

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025 CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025, at 1:30 p.m. MT in Park City, UT. The presentation will include safety findings fr...

April 21, 2025 1 EN
 PRESS RELEASE
Free
DSGN DESIGN THERAPEU...

Design Therapeutics Appoints Veteran Industry Executive Chris Storgard...

Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer CARLSBAD, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of Chris M. Storgard, M.D., as Chief Medical Officer (CMO). Dr. Storgard brings over two decades of leadership and hands-on drug development experience, having successfully advanced multiple assets from preclinical stages through global regulatory approvals. “...

April 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch